Drugmaker Merck seeks EU approval for $41B acquisition of Schering-Plough, expects ruling soonSeptember 21st, 2009 Merck seeks EU approval to buy Schering-PloughTRENTON, N.J. — Drugmaker Merck & Co.
Drugmaker Schering-Plough loses $473 million tax dispute over foreign profits, may appealSeptember 2nd, 2009 Schering-Plough loses $473 million tax disputeTRENTON, N.J. — Drugmaker Schering-Plough Corp.
Judge rejects Schering-Plough's request for $473 million tax refund on overseas profitsSeptember 1st, 2009 Judge rejects Schering-Plough tax refund requestWASHINGTON — A federal court in Newark, N.J. has rejected Schering-Plough Corp.'s request for a $473 million tax refund related to the drugmaker's efforts to avoid paying taxes on $690 million in overseas profits it brought back to the U.S.
Big pharma: Prescription sales and growth trends of the world's top 20 drugmakersAugust 7th, 2009 Ranking Rx: Top 20 drugmakers by annual salesRankings of the world's Top 20 drugmakers, based on global prescription drug sales for the year ending in March 2009, when total pharmaceutical industry revenue grew about 5 percent to more than $720 billion. Figures do not include revenue of company units selling consumer and animal health products, medical devices or diagnostic products.
Merck, Schering-Plough shareholders back $41.1 billion combo to create world's No. 2 drugmakerAugust 7th, 2009 Merck, Schering-Plough shareholders OK $41B dealTRENTON, N.J. — Shareholders of drugmakers Merck & Co.
Shareholders of Merck, Schering-Plough to vote on combination, would create No. 2 drugmakerAugust 7th, 2009 Merck takeover of Schering-Plough up for voteTRENTON, N.J. — Shareholders will decide Friday whether two New Jersey drug companies will become the world's second-biggest drugmaker.
Schering-Plough shareholders back $41.1 billion acquisition by partner Merck & Co.August 7th, 2009 Schering-Plough shareholders OK purchase by MerckTRENTON, N.J. — Shareholders of drugmaker Schering-Plough almost unanimously support being bought by bigger New Jersey neighbor Merck.
Sanofi-Aventis to buy out partner Merck from Merial joint venture for $4 billion in cashJuly 30th, 2009 Sanofi-Aventis pays Merck $4B for share in MerialPARIS — Pharmaceuticals company Sanofi-Aventis SA said Thursday it has agreed to pay $4 billion in cash to U.S. drugmaker Merck & Co.
Schering-Plough 2nd-quarter profit jumps 49 percent as co. records lower 1-time itemsJuly 21st, 2009 Schering-Plough 2nd-quarter profit jumpsTRENTON, N.J. — Drugmaker Schering-Plough Corp.
Merck, Schering to pay $5.4M to resolve probes by 35 states into cholesterol drug studiesJuly 15th, 2009 Merck and Schering-Plough settle investigationNEW YORK — Drugmakers Merck & Co. and Schering-Plough Corp.
Merck and Schering-Plough say antitrust regulators want more details on $41.1B combinationJune 22nd, 2009 FTC requests more info from Merck, Schering-PloughNEW YORK — Drugmakers Merck and Co. and Schering-Plough Corp., which are in the process of a $41.1 billion tie-up, said Monday the Federal Trade Commission has asked for more information about the deal.
Merck mulls selling off veterinary products, its own or Schering-Plough's, before $41B mergerJune 3rd, 2009 Merck may sell animal drug assets before mergerWHITEHOUSE STATION, N.J. — Drugmaker Merck & Co.
Schering-Plough CEO Fred Hassan's compensation falls 34 percent in 2008April 28th, 2009 Schering-Plough CEO's pay falls 34 percent in 2008NEW YORK — Schering-Plough Corp. Chief Executive Fred Hassan's compensation slipped 34 percent in 2008, mainly due to a decline in stock-based awards as the company's share price fell, according to an Associated Press analysis of data filed with regulators Monday.
FDA clears Johnson & Johnson's successor to the blockbuster arthritis drug RemicadeApril 24th, 2009 FDA clears potential blockbuster arthritis drugWASHINGTON — The Food and Drug Administration on Friday approved a potential blockbuster drug from Johnson & Johnson that fights three forms of arthritis caused by immune-system disorders. The injectable medication called Simponi is essentially a follow-up to the multibillion-dollar drug Remicade, which is marketed in the U.S.
Schering-Plough's 1st-quarter profit surges on lower costs, offsetting decline in salesApril 21st, 2009 Schering-Plough 1Q profit jumps despite sales fallNEW YORK — Schering-Plough Corp., in the process of being acquired by competitor Merck & Co., said Tuesday drug sales fell in the first quarter but profit tripled because of cost cutting and a charge in last year's quarter related to an acquisition. The Kenilworth, N.J.-based maker of arthritis treatment Remicade and allergy spray Nasonex earned $767 million, or 46 cents per share.
Loading ...